Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Amarin’s fish oil formulation Vascepa impressed on hard cardiovascular endpoints, but there is confusion about worsening cholesterol in the placebo group.